55 related articles for article (PubMed ID: 3784610)
1. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
Pulley MS; Nagendran V; Edwards JM; Dumonde DC
Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
[TBL] [Abstract][Full Text] [Related]
2. Effects of lymphokines in tumour-bearing patients: clinical and laboratory studies.
Dumonde DC; Pulley MS; Southcott BM; den Hollender FC
Prog Clin Biol Res; 1983; 132E():83-93. PubMed ID: 6647491
[No Abstract] [Full Text] [Related]
3. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
4. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
Adler A; Stein JA; Kedar E; Naor D; Weiss DW
J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
[TBL] [Abstract][Full Text] [Related]
5. Changes induced by local injection of human lymphoid cell lymphokine into dermal metastases of breast carcinoma: a light and electron microscopical study.
Paradinas FJ; Southcott BM; O'Connell D; den Hollander F; Schuurs AH; Pulley MS; Dumonde DC
J Pathol; 1982 Dec; 138(4):309-23. PubMed ID: 7175606
[TBL] [Abstract][Full Text] [Related]
6. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
7. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of sentinel lymph-node biopsy for the staging and treatment of solid neoplasms.
Gipponi M
Minerva Chir; 2005 Aug; 60(4):217-33. PubMed ID: 16166921
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
11. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.
Lotze MT; Hellerstedt B; Stolinski L; Tueting T; Wilson C; Kinzler D; Vu H; Rubin JT; Storkus W; Tahara H; Elder E; Whiteside T
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S109-14. PubMed ID: 9457405
[TBL] [Abstract][Full Text] [Related]
13. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
14. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
15. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
[TBL] [Abstract][Full Text] [Related]
16. [Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Fédération Nationale des Centres de Lutte Contre le Cancer].
Négrier S; Fervers B; Bailly C; Beckendorf V; Cupissol D; Doré JF; Dorval T; Garbay JR; Vilmer C
Bull Cancer; 2000 Feb; 87(2):173-82. PubMed ID: 10705288
[TBL] [Abstract][Full Text] [Related]
17. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
18. Protocol design for lymphokine testing in clinical studies of human cancer.
Lotze MT; Rosenberg SA
Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
[TBL] [Abstract][Full Text] [Related]
19. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
20. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
